A Phase 2/3 interventional study of Plasma-derived AT-III concentrate in Antithrombin III Deficiency, sponsored by Instituto Grifols, S.A.. Terminated. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 2/3, Interventional, and Prevention
Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate in the treatment of subjects with congenital AT-III deficiency.
This study was a prospective, unblinded, non-randomized, open-label, multi-center Phase II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of prophylaxis in surgical interventions and pregnancy/delivery, (Segment II). During the PK segment (Segment I), the subjects were to be remained on their current anticoagulation therapy except for subjects on heparin therapy where a wash-out period of at least 5 half-lives was to be required. In total, 15 subjects with congenital ATIII Deficiency were to be enrolled for the PK assessment (Segment I).
For Segment II, fifteen episodes were to be treated. Recruitment of individual subjects with high risk for venous thrombosis for Segment II of this study was necessary because of the rarity of Antithrombin deficiency in the population.
361 studies on the registry are indexed under Hemostatic Disorders; 65 are open to participants now.
This study's enrollment of 3 is below the median of 60 across 171 interventional studies indexed under Hemostatic Disorders.
Browse Hemostatic Disorders studies →Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Plasma-derived AT-III concentrate
Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI was administered to each patient. Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 through Day 16 (pharmacokinetic parameters estimated using concentration-time data collected during this period)
Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study.
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
Time frame: 30 minutes before the first infusion on Day 1 to Day 16.
Three unique subjects in the United States were enrolled in Study IG401.
| Milestone | Segment I | Segment II |
|---|---|---|
| Started | 2 | 3 |
| Subjects who completed segment i and entered segment ii | 1 | 0 |
| Subjects whose samples were assessed for pk | 2 | 0 |
| Total number of clinical events | 0 | 3 |
| Parturition | 0 | 2 |
| Surgical removal of compound melanocytic nevus | 0 | 1 |
| Completed | 2 | 3 |
| Not completed | 0 | 0 |
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| hours | Subject 1 Chromogenic Unadjusted | Subject 1 Chromogenic Baseline Adjusted | Subject 2 Chromogenic Unadjusted | Subject 2 Chromogenic Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study. | 241.65 | 421.63 | 285.05 | 97.13 |
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| h*mg/dL | Subject 1 Chromogenic Unadjusted | Subject 1 Chromogenic Baseline Adjusted | Subject 2 Chromogenic Unadjusted | Subject 2 Chromogenic Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study. | 44974.51 | 3175.24 | 48610.54 | 6788.75 |
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| hours | Subject 1 Chromogenic Unadjusted | Subject 1 Chromogenic Baseline Adjusted | Subject 2 Chromogenic Unadjusted | Subject 2 Chromogenic Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study. | 434.03 | 385.31 | 475.74 | 171.44 |
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| IU/kg/[mg/dL] | Subject 1 Chromogenic Unadjusted | Subject 1 Chromogenic Baseline Adjusted | Subject 2 Chromogenic Unadjusted | Subject 2 Chromogenic Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study. | 0.4825 | 6.0674 | 0.4893 | 1.2627 |
Assess the pharmacokinetic profile of parameters T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\] of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Chromogenic assay data reported in % was used for pharmacokinetic parameter estimation. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| IU/kg/[hr*mg/dL] | Subject 1 Chromogenic Unadjusted | Subject 1 Chromogenic Baseline Adjusted | Subject 2 Chromogenic Unadjusted | Subject 2 Chromogenic Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Chromogenic Methods for Subjects Enrolled in Segment 1 of the Study. | 0.0011 | 0.0157 | 0.0010 | 0.0074 |
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| hours | Subject 1 Radial Immunodiffusions Unadjusted | Subject 1 Radial Immunodiffusions Baseline Adjusted | Subject 2 Radial Immunodiffusions Unadjusted | Subject 2 Radial Immunodiffusions Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (T1/2) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study. | 249.54 | 48.75 | 244.06 | 69.11 |
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| h*mg/dL | Subject 1 Radial Immunodiffusions Unadjusted | Subject 1 Radial Immunodiffusions Baseline Adjusted | Subject 2 Radial Immunodiffusions Unadjusted | Subject 2 Radial Immunodiffusions Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (AUC) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study. | 14591.55 | 1066.92 | 14697.16 | 2422.27 |
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Pharmacokinetic parameters were estimated using noncompartmental analysis of antithrombin concentration-time data collected from Day 1 through Day 16. Reported values are derived estimates based on the concentration-time profile and may include extrapolation beyond the last measurable concentration, where applicable. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| hours | Subject 1 Radial Immunodiffusions Unadjusted | Subject 1 Radial Immunodiffusions Baseline Adjusted | Subject 2 Radial Immunodiffusions Unadjusted | Subject 2 Radial Immunodiffusions Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (MRT) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study. | 428.02 | 69.33 | 392.25 | 126.16 |
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| IU/kg/[mg/dL] | Subject 1 Radial Immunodiffusions Unadjusted | Subject 1 Radial Immunodiffusions Baseline Adjusted | Subject 2 Radial Immunodiffusions Unadjusted | Subject 2 Radial Immunodiffusions Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (Vdss) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study. | 1.4667 | 3.2492 | 1.3344 | 2.6042 |
Assess the pharmacokinetic profile of T1/2, area under the curve \[AUC\], mean residence time \[MRT\], volume of distribution at steady-state \[Vdss\], and clearance of substrate \[CL\]) of AT-III in congenital AT-III deficient patients. AT PK parameters were determined by two methods: chromogenic to determine the activity of AT, and radial immunodiffusion to determine the antigen of AT. Due to the small number of subjects in Segment I, no data integration across the 2 subjects nor statistical analysis of these PK parameters were performed.
| IU/kg/[hr*mg/dL] | Subject 1 Radial Immunodiffusions Unadjusted | Subject 1 Radial Immunodiffusions Baseline Adjusted | Subject 2 Radial Immunodiffusions Unadjusted | Subject 2 Radial Immunodiffusions Baseline Adjusted |
|---|---|---|---|---|
| Assess the Pharmacokinetic Profile (CL) of Anbinex® Using Radial Immunodiffusion Methods for Subjects Enrolled in Segment 1 of the Study. | 0.0034 | 0.0469 | 0.0034 | 0.0206 |
Collected over Up to Month 6. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Segment I | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Segment II | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | Segment I | Segment II |
|---|---|---|
| CellulitisInfections and infestations | 1/2 | 0/2 |
| Event | Segment I | Segment II |
|---|---|---|
| FatigueGeneral disorders | 1/2 | 1/2 |
| CellulitisInfections and infestations | 1/2 | 0/2 |
The intent-to-treat (ITT) population includes all subjects who were enrolled and received at least 1 ATIII-DAF/DI infusion. Segment II includes 1 subject who enrolled in both Segments I and II. Segment II also includes 1 subject who was assigned 2 subject numbers due to 2 clinical events of pregnancy.
| Age, Continuous(years) | Segment I | Segment II | Total |
|---|---|---|---|
| Mean | 26.0 ± 1.41 | 36.0 ± 6.24 | 33 ± 11.3 |
| Sex: Female, Male(Participants) | Segment I | Segment II | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Segment I | Segment II | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 2 | 3 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Segment I | Segment II | Total |
|---|---|---|---|
| Caucasian | 2 | 3 | 5 |
| African-American | 0 | 0 | 0 |
| American Indian | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
No study locations are listed for this record.
Ran from Apr 2008 to primary completion in Dec 2011, 44 months.
Results were first posted in Oct 2026, 14 years 10 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Jan 2006 → Apr 2008, primary completion Dec 2028 → Dec 2011 and completion Mar 2029 → Dec 2011.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
Due to recruitment challenges during the trial, this study was terminated early by the Sponsor.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.